Lucid Diagnostics Inc [LUCD] stock is trading at $1.59, up 19.55%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LUCD shares have gain 26.19% over the last week, with a monthly amount glided 19.55%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lucid Diagnostics Inc [NASDAQ: LUCD] stock has seen the most recent analyst activity on December 27, 2021, when Ascendiant Capital Markets initiated its Buy rating and assigned the stock a price target of $16. Previously, Needham started tracking the stock with Buy rating on November 08, 2021, and set its price target to $17. On November 08, 2021, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $21 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $14 on November 08, 2021.
Lucid Diagnostics Inc [LUCD] stock has fluctuated between $0.68 and $1.80 over the past year. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. Lucid Diagnostics Inc [NASDAQ: LUCD] shares were valued at $1.59 at the most recent close of the market. An investor can expect a potential return of 25.79% based on the average LUCD price forecast.
Analyzing the LUCD fundamentals
Lucid Diagnostics Inc [NASDAQ:LUCD] reported sales of 4.17M for the trailing twelve months, which represents a drop of -17.28%. Gross Profit Margin for this corporation currently stands at -0.87% with Operating Profit Margin at -15.06%, Pretax Profit Margin comes in at -32.41%, and Net Profit Margin reading is -43.37%. To continue investigating profitability, this company’s Return on Assets is posted at -1.1, Equity is 26.96 and Total Capital is 3.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.56.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4200 points at the first support level, and at 1.2500 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6800, and for the 2nd resistance point, it is at 1.7700.
Ratios To Look Out For
For context, Lucid Diagnostics Inc’s Current Ratio is 0.75. Further, the Quick Ratio stands at 0.72, while the Cash Ratio is 0.69. Considering the valuation of this stock, the price to sales ratio is 41.25.
Transactions by insiders
Recent insider trading involved Matheis Dennis, Director, that happened on May 20 ’25 when 0.19 million shares were purchased. Director, Matheis Dennis completed a deal on May 21 ’25 to buy 0.13 million shares. Meanwhile, Director Matheis Dennis bought 33218.0 shares on May 22 ’25.
